Literature DB >> 19268501

ARHGAP21 modulates FAK activity and impairs glioblastoma cell migration.

Carolina Louzão Bigarella1, Luciene Borges, Fernando Ferreira Costa, Sara Terezinha Olalla Saad.   

Abstract

Glioblastoma multiforme is highly aggressive and is the most common glial tumor type. Although there have been advances in treatment, the average survival expectancy is 12-15 months. Several genes have been shown to influence glioblastoma progression. In the present work, we demonstrate that the RhoGTPase Activating Protein 21 (ARHGAP21) is expressed in the nuclear and perinuclear regions of several cell lines. In T98G and U138MG, glioblastoma derived cell lines, ARHGAP21 interacts with the C-terminal region of Focal Adhesion Kinase (FAK). ARHGAP21 depletion by shRNAi in T98G cells alters cellular morphology and increases: FAK phosphorylation states and activation of downstream signaling; the activity state of Cdc42; the production of metalloproteinase 2 (MMP-2) and cell migration rates. These modifications were found to be mainly due to the loss of ARHGAP21 action on FAK and, consequently, the activation of downstream effectors. These results suggest not only that ARHGAP21 might act as a tumor suppressor gene, but also indicate that ARHGAP21 might be a master regulator of migration having a crucial role in controlling the progression of different tumor types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268501     DOI: 10.1016/j.bbamcr.2009.02.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

1.  ARHGAP21 protein, a new partner of α-tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition.

Authors:  Karin S A Barcellos; Carolina L Bigarella; Mark V Wagner; Karla P Vieira; Mariana Lazarini; Peter R Langford; João A Machado-Neto; Steven G Call; Davis M Staley; Jarom Y Chung; Marc D Hansen; Sara T O Saad
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

2.  Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Authors:  Fadila Guessous; Yanzhi Yang; Elizabeth Johnson; Lukasz Marcinkiewicz; Matthew Smith; Ying Zhang; Alexander Kofman; David Schiff; James Christensen; Roger Abounader
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

3.  The Actin Cytoskeleton Mediates Transmission of "Candidatus Liberibacter solanacearum" by the Carrot Psyllid.

Authors:  Poulami Sarkar; Svetlana Kontsedalov; Galina Lebedev; Murad Ghanim
Journal:  Appl Environ Microbiol       Date:  2021-01-15       Impact factor: 4.792

Review 4.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

5.  Identification of rare cancer driver mutations by network reconstruction.

Authors:  Ali Torkamani; Nicholas J Schork
Journal:  Genome Res       Date:  2009-07-02       Impact factor: 9.043

6.  A potential Rho GEF and Rac GAP for coupled Rac and Rho cycles during mesenchymal-to-epithelial-like transitions.

Authors:  Christopher P Toret; Andre Le Bivic
Journal:  Small GTPases       Date:  2018-08-29

7.  Increased AT1 receptor expression mediates vasoconstriction leading to hypertension in Snx1-/- mice.

Authors:  Chao Liu; Xingyue Li; Jinjuan Fu; Ken Chen; Qiao Liao; Jialiang Wang; Caiyu Chen; Hao Luo; Pedro A Jose; Yongjian Yang; Jian Yang; Chunyu Zeng
Journal:  Hypertens Res       Date:  2021-05-10       Impact factor: 3.872

Review 8.  Crosstalk of small GTPases at the Golgi apparatus.

Authors:  Francesco Baschieri; Hesso Farhan
Journal:  Small GTPases       Date:  2012 Apr-Jun

Review 9.  Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression.

Authors:  Shannon Patricia Fortin Ensign; Ian T Mathews; Marc H Symons; Michael E Berens; Nhan L Tran
Journal:  Front Oncol       Date:  2013-10-04       Impact factor: 6.244

10.  CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.

Authors:  Rita de Cássia Carvalho Melo; Ana Leda Longhini; Carolina Louzão Bigarella; Mariana Ozello Baratti; Fabiola Traina; Patrícia Favaro; Paula de Melo Campos; Sara Teresinha Olalla Saad
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.